BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

Free Newsletters
My Subscriptions

News by Subject
News by Disease
News by Date
Search News
Post Your News

Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Pharm Country
  Bio NC
  Southern Pharm
  BioCanada East
  US Device


Company Profiles

Research Store

Research Events
Post an Event
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile


Alnylam Pharmaceuticals 

300 Third Street

Cambridge  Massachusetts  02142  U.S.A.
Phone: 617-551-8200 Fax: 617-551-8101


View Clinical Trials from BioPharm Insight

Alnylam Pharmaceuticals (NASDAQ: ALNY) is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is leading the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases, including ALN-TTR for the treatment of transthyretin-mediated amyloidosis (ATTR), ALN-PCS for the treatment of severe hypercholesterolemia, ALN-HPN for the treatment of refractory anemia, and ALN-APC for the treatment of hemophilia. As part of its “Alnylam 5x15TM” strategy, the company expects to have five RNAi therapeutic products for genetically defined diseases in advanced stages of clinical development by the end of 2015. Alnylam has additional partner-based programs in clinical or development stages, including ALN-RSV01 for the treatment of respiratory syncytial virus (RSV) infection, ALN-VSP for the treatment of liver cancers, and ALN-HTT for the treatment of Huntington’s disease.

The company’s leadership position on RNAi therapeutics and intellectual property have enabled it to form major alliances with leading companies including Merck, Medtronic, Novartis, Biogen Idec, Roche, Takeda, Kyowa Hakko Kirin, and Cubist. In addition, Alnylam and Isis co-founded Regulus Therapeutics Inc., a company focused on discovery, development, and commercialization of microRNA therapeutics; Regulus has formed partnerships with GlaxoSmithKline and Sanofi. Alnylam has also formed Alnylam Biotherapeutics, a division of the company focused on the development of RNAi technologies for application in biologics manufacturing, including recombinant proteins and monoclonal antibodies. Alnylam scientists and collaborators have published their research on RNAi therapeutics in over 100 peer-reviewed papers, including many in the world’s top scientific journals such as Nature, Nature Medicine, Nature Biotechnology, and Cell.

 Key Statistics

Ownership: Public

Web Site: Alnylam Pharmaceuticals
Symbol: ALNY



Cubist Pharmaceuticals, Inc. 

 Company News
Alnylam Pharmaceuticals (ALNY)’s McSwiggen Patent Upheld in European Opposition Proceedings 4/7/2014 10:09:50 AM    More...
Alnylam Pharmaceuticals (ALNY) To Webcast Presentation At 13th Annual Needham Healthcare Conference 4/3/2014 8:47:28 AM    More...
Alnylam Pharmaceuticals (ALNY) Receives Positive Opinion For Orphan Drug Designation In The European Union For ALN-Ttrsc, A Subcutaneously Delivered Rnai Therapeutic For The Treatment Of Transthyretin-Mediated Amyloidosis (ATTR) 4/2/2014 10:22:59 AM    More...
Genzyme Corporation (GENZ) Exercises Its Right To Purchase Additional Shares Of Alnylam Pharmaceuticals (ALNY) Common Stock 3/26/2014 9:33:32 AM    More...
Genzyme Corporation (GENZ) Exercises Right To Increase Stake In Alnylam Pharmaceuticals (ALNY) 3/26/2014 7:04:33 AM    More...
Alnylam Pharmaceuticals (ALNY) To Present Data From Its RNAi Therapeutic Programs Targeting Transthyretin (TTR) For The Treatment Of TTR-Mediated Amyloidosis (ATTR) At XIVth International Symposium On Amyloidosis (ISA) 3/21/2014 6:31:51 AM    More...
Alnylam Pharmaceuticals (ALNY) To Webcast Presentation At Barclays Global Healthcare Conference 3/7/2014 6:44:28 AM    More...
Alnylam Pharmaceuticals (ALNY) Announces Closing Of Previously Announced Acquisition Of Merck & Co., Inc. (MRK)'s Sirna Therapeutics, Inc. (RNAI) Subsidiary 3/6/2014 9:46:12 AM    More...
Alnylam Pharmaceuticals (ALNY) Announces Closing of Previously Announced Alliance With Genzyme Corporation (GENZ) For Discovery, Development, And Commercialization Of RNAi Therapeutics As Genetic Medicines 2/28/2014 9:18:02 AM    More...
Alnylam Pharmaceuticals (ALNY) To Webcast Presentation At Cowen and Company 34th Annual Health Care Conference 2/26/2014 6:48:44 AM    More...